203 related articles for article (PubMed ID: 10195881)
1. Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma.
Kanno H; Hattori S; Sato H; Murata H; Huang FH; Hayashi A; Suzuki N; Yamamoto I; Kawamoto S; Minami M; Miyatake S; Shuin T; Kaplitt MG
Cancer Gene Ther; 1999; 6(2):147-54. PubMed ID: 10195881
[TBL] [Abstract][Full Text] [Related]
2. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
[TBL] [Abstract][Full Text] [Related]
3. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of herpes simplex virus vectors expressing murine alpha 1-interferon.
Mester JC; Pitha PM; Glorioso JC
Gene Ther; 1995 May; 2(3):187-96. PubMed ID: 7614249
[TBL] [Abstract][Full Text] [Related]
5. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
6. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
Toda M; Martuza RL; Rabkin SD
Mol Ther; 2000 Oct; 2(4):324-9. PubMed ID: 11020347
[TBL] [Abstract][Full Text] [Related]
7. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
10. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
[TBL] [Abstract][Full Text] [Related]
11. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
Miyatake S; Martuza RL; Rabkin SD
Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507
[TBL] [Abstract][Full Text] [Related]
12. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
[TBL] [Abstract][Full Text] [Related]
14. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
15. Th1-associated immune responses to beta-galactosidase expressed by a replication-defective herpes simplex virus.
Brubaker JO; Thompson CM; Morrison LA; Knipe DM; Siber GR; Finberg RW
J Immunol; 1996 Aug; 157(4):1598-604. PubMed ID: 8759744
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse.
Natsume A; Mizuno M; Ryuke Y; Yoshida J
Gene Ther; 1999 Sep; 6(9):1626-33. PubMed ID: 10490773
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration.
Niranjan A; Moriuchi S; Lunsford LD; Kondziolka D; Flickinger JC; Fellows W; Rajendiran S; Tamura M; Cohen JB; Glorioso JC
Mol Ther; 2000 Aug; 2(2):114-20. PubMed ID: 10947938
[TBL] [Abstract][Full Text] [Related]
18. [Gene therapy by in vivo interferon-gamma gene transfer to murine bladder tumor].
Hashimura T; Ueda T; Hiura M; Yoshida O; Kawabata K; Watanabe Y; Takami M
Hinyokika Kiyo; 1997 Nov; 43(11):809-13. PubMed ID: 9436027
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA.
Nishihara K; Miyatake S; Sakata T; Yamashita J; Kikuchi H; Kawade Y; Zu Y; Namba Y; Hanaoka M; Watanabe Y
Cancer Res; 1988 Sep; 48(17):4730-5. PubMed ID: 3136912
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
